Clinical Trial Update: Study of Imatinib Mesylate in Combination With Hydroxyurea Versus Hydroxyurea Alone as an Oral Therapy in Patients With Temozolomide Resistant Progressive Glioblastoma [Phase 3]

View source ↗

Summary

Phase 3 trial comparing imatinib mesylate with hydroxyurea versus hydroxyurea alone in temozolomide-resistant progressive glioblastoma; study completed with res…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Astrocytoma
• Glioblastoma

Drugs mentioned

• Gleevec (Imatinib)
• HYDROXYUREA (Hydroxyurea)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Glioblastoma Multiforme, Astrocytoma | Phase 3 | Status: COMPLETED | Results posted: 2011-02-02